Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 43.27% is 122% above its 5-year average of 19.53%, near the high end of its 5-year range (-43.70%–43.27%).
As of the fiscal period ended Tuesday, June 30, 2026. 36.52% above its 12-month average of 31.69%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
43.27%
EBITDA MARGIN AVG TTM
31.69%
EBITDA MARGIN AVG 3Y
23.78%
EBITDA MARGIN AVG 5Y
22.69%
EBITDA MARGIN AVG 10Y
20.38%
EBITDA MARGIN AVG 15Y
14.33%
EBITDA MARGIN AVG 20Y
-6.16%
CURRENT VS TTM AVG
+36.52%
CURRENT VS 3Y AVG
+81.98%
CURRENT VS 5Y AVG
+90.70%
CURRENT VS 10Y AVG
+112.35%
CURRENT VS 15Y AVG
+202.06%
CURRENT VS 20Y AVG
+802.47%
Incyte Corporation
Market Cap
$24.28B
EBITDA Margin
43.27%
TTM Avg
31.69%
3Y Avg
23.78%
5Y Avg
22.69%
Market Cap
$24.72B
EBITDA Margin
24.13%
TTM Avg
25.03%
3Y Avg
27.36%
5Y Avg
27.53%
Market Cap
$25.74B
EBITDA Margin
15.75%
TTM Avg
14.53%
3Y Avg
14.10%
5Y Avg
17.90%
Market Cap
$26.03B
EBITDA Margin
19.69%
TTM Avg
19.16%
3Y Avg
18.89%
5Y Avg
21.02%
Market Cap
$26.07B
EBITDA Margin
34.73%
TTM Avg
34.58%
3Y Avg
34.05%
5Y Avg
33.84%
Market Cap
$22.32B
EBITDA Margin
-147.07%
TTM Avg
-132.24%
3Y Avg
-66.39%
5Y Avg
-46.73%
Market Cap
$22.03B
EBITDA Margin
50.36%
TTM Avg
50.37%
3Y Avg
51.80%
5Y Avg
47.75%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incyte Corporation (INCY) | $24.28B | 43.27% | 31.69% | 23.78% | 22.69% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.72B | 24.13% | 25.03% | 27.36% | 27.53% |
| BioNTech SE (BNTX)vs › | $23.16B | -9.29% | -23.11% | 12.60% | 20.38% |
| Labcorp Holdings Inc. (LH)vs › | $25.74B | 15.75% | 14.53% | 14.10% | 17.90% |
| STERIS plc (STE)vs › | $22.68B | 26.76% | 25.68% | 26.35% | 25.75% |
| Quest Diagnostics Incorporated (DGX)vs › | $26.03B | 19.69% | 19.16% | 18.89% | 21.02% |
| Waters Corporation (WAT)vs › | $26.07B | 34.73% | 34.58% | 34.05% | 33.84% |
| Moderna, Inc. (MRNA)vs › | $22.32B | -147.07% | -132.24% | -66.39% | -46.73% |
| United Therapeutics Corporation (UTHR)vs › | $22.03B | 50.36% | 50.37% | 51.80% | 47.75% |
| Viatris Inc. (VTRS)vs › | $20.55B | 0.95% | 10.32% | 17.98% | 18.96% |
Gross Margin
92.6%
EBITDA Margin
43.3%
Operating Margin
31.6%
Net Margin
27.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 43.27% |
| 2026-03-31 | 27.34% |
| 2025-12-31 | 27.07% |
| 2025-09-30 | 33.33% |
| 2025-06-30 | 27.46% |
| 2025-03-31 | 22.71% |
| 2024-12-31 | 27.16% |
| 2024-09-30 | 14.82% |
| 2024-06-30 | -43.70% |
| 2024-03-31 | 12.92% |
| 2023-12-31 | 20.63% |
| 2023-09-30 | 25.69% |
| 2023-06-30 | 22.43% |
| 2023-03-31 | 5.44% |
| 2022-12-31 | 9.53% |
| 2022-09-30 | 18.83% |
| 2022-06-30 | 29.73% |
| 2022-03-31 | 18.14% |
| 2021-12-31 | 14.56% |
| 2021-09-30 | 30.76% |
| 2021-06-30 | 22.01% |
| 2021-03-31 | 18.63% |
| 2020-12-31 | 22.47% |
| 2020-09-30 | 2.94% |
| 2020-06-30 | 35.37% |
| 2020-03-31 | -114.49% |
| 2019-12-31 | 18.70% |
| 2019-09-30 | 26.86% |
| 2019-06-30 | 21.14% |
| 2019-03-31 | 17.67% |
| 2018-12-31 | 18.21% |
| 2018-09-30 | 9.99% |
| 2018-06-30 | 18.55% |
| 2018-03-31 | -14.04% |
| 2017-12-31 | -26.96% |
| 2017-09-30 | 7.07% |
| 2017-06-30 | 6.01% |
| 2017-03-31 | -30.78% |
| 2016-12-31 | 18.27% |
| 2016-09-30 | 14.56% |
| 2016-06-30 | 23.32% |
| 2016-03-31 | 17.88% |
| 2015-12-31 | 31.03% |
| 2015-09-30 | 5.90% |
| 2015-06-30 | 2.38% |
| 2015-03-31 | 3.08% |
| 2014-12-31 | -10.81% |
| 2014-09-30 | 40.28% |
| 2014-06-30 | -16.56% |
| 2014-03-31 | -14.83% |
| 2013-12-31 | -7.51% |
| 2013-09-30 | -10.12% |
| 2013-06-30 | 24.95% |
| 2013-03-31 | 5.12% |
| 2012-12-31 | 33.40% |
| 2012-09-30 | -4.24% |
| 2012-06-30 | 26.14% |
| 2012-03-31 | -74.50% |
| 2011-12-31 | -128.41% |
| 2011-09-30 | -209.95% |
| 2011-06-30 | -205.03% |
| 2011-03-31 | -29.38% |
| 2010-12-31 | 57.22% |
| 2010-09-30 | -98.85% |
| 2010-06-30 | 39.14% |
| 2010-03-31 | -77.71% |
| 2009-12-31 | -494.45% |
| 2009-09-30 | -2906.28% |
| 2009-06-30 | -3815.21% |
| 2009-03-31 | -4729.81% |
| 2008-12-31 | -4201.07% |
| 2008-09-30 | -3444.20% |
| 2008-06-30 | -6096.25% |
| 2008-03-31 | -2512.39% |
| 2007-12-31 | -248.00% |
| 2007-09-30 | -270.88% |
| 2007-06-30 | -122.22% |
| 2007-03-31 | -230.18% |
| 2006-12-31 | -230.84% |
| 2006-09-30 | -198.89% |
| 2006-06-30 | -261.87% |
| 2006-03-31 | -321.11% |
| 2005-12-31 | -2423.93% |
| 2005-09-30 | -2050.65% |
| 2005-06-30 | -984.75% |
| 2005-03-31 | -553.69% |
| 2004-12-31 | 2962.45% |
| 2004-09-30 | -688.72% |
| 2004-06-30 | -1426.01% |
| 2004-03-31 | -549.83% |
| 2003-12-31 | -328.15% |
| 2003-09-30 | -193.72% |
| 2003-06-30 | -202.39% |
| 2003-03-31 | -398.24% |
| 2002-12-31 | -58.76% |
| 2002-09-30 | -142.27% |
